Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical Co has a Cash Ratio of 0.72. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Wakamoto Pharmaceutical Co's Cash Ratio or its related term are showing as below:
TSE:4512'
s Cash Ratio Range Over the Past 10 Years
Min: 0.72 Med: 1.53 Max: 2.03
Current: 0.77
During the past 13 years, Wakamoto Pharmaceutical Co's highest Cash Ratio was 2.03. The lowest was 0.72. And the median was 1.53.
TSE:4512's Cash Ratio is ranked better than 57.82% of 965
companies
in the Drug Manufacturers industry
Industry Median: 0.58
vs TSE:4512: 0.77
Wakamoto Pharmaceutical Co (TSE:4512) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Wakamoto Pharmaceutical Co Cash Ratio Related Terms
Wakamoto Pharmaceutical Co Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co (TSE:4512) has a Cash Ratio of 0.72 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Wakamoto Pharmaceutical Co and its competitors. This is 53% below median its historical median of 1.53. Over the past decade, Wakamoto Pharmaceutical Co's Cash Ratio has ranged from 0.72 to 2.03. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #407 out of 965 companies in the Drug Manufacturers industry, placing it in the top 42.2%.
Is Wakamoto Pharmaceutical Co's Cash Ratio too high?
Wakamoto Pharmaceutical Co's current Cash Ratio of 0.72 is 53% below median its 10-year median of 1.53. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 2.03. The Drug Manufacturers industry median Cash Ratio is 0.58. Wakamoto Pharmaceutical Co's value of 0.72 is 24.1% above this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #407 out of 965 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Cash Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #407 out of 965 companies for Cash Ratio. This puts Wakamoto Pharmaceutical Co in the upper half of its industry. The industry median Cash Ratio is 0.58. Wakamoto Pharmaceutical Co's value of 0.72 is 24.1% above this benchmark. Historically, Wakamoto Pharmaceutical Co's own Cash Ratio has ranged from 0.72 to 2.03 over the past decade. While the company's 10-year median is 1.53 vs. the industry median of 0.58, Wakamoto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.58, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current Cash Ratio of 0.72 is 24.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Wakamoto Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current Cash Ratio is 0.72, which is 53% below median its own 10-year median of 1.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Fairly Valued. The stock's GF Value™ is 円309.92, compared to a current price of 円314.00 — trading 1.3% above its estimated fair value. The current Cash Ratio is 0.72, which is 53% below median its 10-year median of 1.53 and 24.1% above the Drug Manufacturers industry median of 0.58. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Cash Ratio is 0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円314.00 is trading 1.3% above its estimated GF Value™ of 円309.92.
GuruFocus considers Wakamoto Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4512:
Cash Ratio: 0.72 (53% below median its 10-year median of 1.53)
GF Value™: 円309.92 vs. price of 円314.00 (1.3% above fair value)
Industry Position: 24.1% above the Drug Manufacturers median (#407 of 965)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score
Get the complete analysis for TSE:4512
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
